Horizon Pharma (HZNP) Wins IPR Ruling Upholding Patent on Ravicti Drug - Bloomberg
- Indexes hit record highs as Trump rally continues
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- Lower for longer, ECB scales back asset buys
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Oil rises above $50 on renewed hopes for output cuts
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Horizon Pharma (NASDAQ: HZNP) Wins IPR Ruling Upholding Patent on Ravicti Drug - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Horizon Pharma (HZNP) Announces ACTIMMUNE Phase 3 in FA Missed Primary Endpoint
- TETRA Technologies (TTI) Offers Q4 Update; Says Considering Capital Raise Options
- Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich's Ataxia
Create E-mail Alert Related CategoriesCorporate News, Litigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!